A5028707750- Multiple Myeloma Research and Treatments
- Peptidase Inhibition and Analysis
- Chronic Lymphocytic Leukemia Research
- Cancer Treatment and Pharmacology
- Monoclonal and Polyclonal Antibodies Research
- Protein Degradation and Inhibitors
- Bone health and treatments
- Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Synthesis and Biological Evaluation
- Immunodeficiency and Autoimmune Disorders
- Cancer therapeutics and mechanisms
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Glycosylation and Glycoproteins Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Protease and Inhibitor Mechanisms
- HIV/AIDS drug development and treatment
- Calcium signaling and nucleotide metabolism
- Bone Metabolism and Diseases
- Blood Coagulation and Thrombosis Mechanisms
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Quinazolinone synthesis and applications
- Radiopharmaceutical Chemistry and Applications
Vejle Sygehus
2016-2025
University of Southern Denmark
2016-2025
Lillebaelt Hospital
2008-2024
Copenhagen University Hospital
2023
Region of Southern Denmark
2007-2019
Aarhus University Hospital
2018
Wilhelminen Hospital
2018
Irmandade da Santa Casa de Misericórdia de São Paulo
2017
Erasmus University Rotterdam
2017
Erasmus MC
2017
Daratumumab showed promising efficacy alone and with lenalidomide dexamethasone in a phase 1–2 study involving patients relapsed or refractory multiple myeloma.
Multiple myeloma cells uniformly overexpress CD38. We studied daratumumab, a CD38-targeting, human IgG1κ monoclonal antibody, in phase 1-2 trial involving patients with relapsed or that was refractory to two more prior lines of therapy.In part 1, the dose-escalation phase, we administered daratumumab at doses 0.005 24 mg per kilogram body weight. In 2, dose-expansion 30 received 8 and 42 16 kilogram, once weekly (8 doses), twice monthly for up months. End points included safety, efficacy,...
Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible autologous stem-cell transplantation. We sought to determine whether the addition of daratumumab would significantly reduce risk disease progression or death in this population.
Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter, randomized study compared melphalan-prednisone-lenalidomide induction followed by lenalidomide maintenance (MPR-R) with (MPR) or melphalan-prednisone (MP) placebo in patients 65 years of age older newly diagnosed myeloma.We randomly assigned who were ineligible for transplantation to receive MPR-R (nine 4-week cycles MPR therapy until a relapse disease progression occurred...
Abstract In the phase 3 MAIA study of patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab plus lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) versus (Rd). We present a subgroup analysis by frailty status. Frailty assessment was performed retrospectively using age, Charlson comorbidity index, and baseline Eastern Cooperative Oncology Group performance status score. Patients were classified as fit, intermediate, non-frail (fit +...
PURPOSE With the initial analysis of POLLUX at a median follow-up 13.5 months, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly prolonged progression-free survival versus (Rd) alone patients relapsed or refractory multiple myeloma (RRMM). We report updated efficacy safety results time final for overall (OS). METHODS was multicenter, randomized, open-label, phase III study during which eligible ≥ 1 line prior therapy were randomly assigned 1:1 to D-Rd Rd...
Multiple myeloma is characterized by the accumulation of clonal malignant plasma cells in bone marrow, which stimulates destruction osteoclasts and reduces formation osteoblasts. In turn, changed microenvironment sustains survival cells. Therefore, a challenge for treating multiple discovering drugs targeting not only but also Because resveratrol (trans-3,4',5-trihydroxystilbene) reported to display antitumor activities on variety human cancer cells, we investigated effects this natural...
Abstract For decades, conventional skeletal survey (CSS) has been the standard imaging technique for multiple myeloma (MM). However, recently whole-body computed tomography (WBCT) implemented into diagnostic criteria of MM. This analysis compares sensitivity and prognostic significance WBCT CSS in patients with smoldering MM (SMM) Fifty-four 212 (25.5%) had a negative positive osteolytic lesions ( P <0.0001). Of 66 SMM based on CSS, 12 (22.2%) WBCT. In comparison, failed to detect some...
Daratumumab treatment results in a marked reduction of CD38 expression on multiple myeloma cells. The aim this study was to investigate the clinical implications and underlying mechanisms daratumumab-mediated reduction.
Summary The impact of first‐line treatment with the anti‐ CD 20 chimeric monoclonal antibody rituximab in patients warm‐antibody reactive autoimmune haemolytic anaemia ( WAIHA ) is unknown. We report first randomized study 64 newly diagnosed who received prednisolone and combined N = 32) or monotherapy 32). After 12 months, a satisfactory response was observed 75% treated but significantly smaller proportion (36%) those given alone P 0·003). Furthermore, relapse‐free survival better after...
Abstract Daratumumab is a CD38‐targeted human monoclonal antibody with direct anti‐myeloma cell mechanisms of action. Flow cytometry in relapsed and/or refractory multiple myeloma (RRMM) patients treated daratumumab revealed cytotoxic T‐cell expansion and reduction immune‐suppressive populations, suggesting immune modulation as an additional mechanism Here, we performed in‐depth analysis the effects on immune‐cell subpopulations using high‐dimensional mass cytometry. Whole‐blood bone‐marrow...
Abstract Monoclonal antibodies are promising anti-myeloma treatments. As immunoglobulins, monoclonal have the potential to be identified by serum protein electrophoresis (SPE) and immunofixation (IFE). Therapeutic antibody interference with standard clinical SPE IFE can confound use of these tests for response assessment in trials disease monitoring. To discriminate between endogenous myeloma daratumumab, a daratumumab-specific reflex assay (DIRA) was developed using mouse anti-daratumumab...